biomaterials-materials-physics-2019-keynote

15 / 24

allied
academies
May 20-21, 2019 | Vienna, Austria
Biomaterials and Nanomaterials &
Materials Physics and Materials Science
2nd International Conference on
Page 38
Journal of Materials Science and Nanotechnology | Volume 3
Chin Tarng Lin
National Taiwan University, Taiwan
Verification of the efficacy of targeting peptides linked liposomal
nanoparticles for therapy of different cancers
The efficacy of systemic cytotoxic chemotherapy has
been widely assessed in patients with advanced
hepatocellular carcinoma (HCC). For example, doxorubicin
is the most commonly studied chemotherapeutic agent
for HCC. However, it has been shown to have a response
rate of only 10-20% in clinical trial. In addition, its potential
benefit has been reduced by the related adverse effect. So
far, the multi kinase inhibitor, sorafenib, is considered to
provide survival benefit over supportive care. However, the
long-term prognosis of those cancer patients still remains
poor. Therefore, in the present experiment, we proposed
to use the so-called peptide targeting chemotherapy to
overcome the adverse event in the conventional targeted
chemotherapy. In order to perform this experiment,
we have constructed some specific peptides which can
bind specifically to the cancer cells and cancer vascular
endothelia by using a phage displayed 12-mer random
peptide library. We have obtained 3 different peptides
and one control peptide. Each contains 12 amino acids:
a. L-peptide: RLLDTNRPLLPY (anti-different cancer cell
membrane); b. control peptide: RLLDTNRGGGGG; c. SP-94-
peptide: SFSHHTPILP (anti-NPC tumor cell and hepatoma
cell membranes) and d. PC5-52-peptide: SVSVGMKPSPRP
(anti-tumor endothelia). Those L-peptide (L-P), SP-
peptide (SP-P), PC5-52-peptide and a control peptide
(C-P) were linked to liposomal iron oxide nanoparticles;
and to liposomal doxorubicin (L-D). Using peptide linked
liposomal iron oxide, we can localize the peptide targeted
tumor cells and tumor endothelia, and then we used those
peptides linked liposomal doxorubicin to treat SCID mice
bearing different cancer xenografts. Our results showed
that when L-P-L-D containing 2mg/kg of SCID mouse body
weight was used to treat xenografts bearing SCID mice, the
tumor could be well controlled, and no specific adverse
event was seen. However, when the control peptide was
used to replace the specific peptide, the xenograft size
was decreased, but the visceral organs revealed marked
apoptotic change. In conclusion, the specific peptides
linked liposomal doxorubicin nanoparticles can be used
for treatment of SCID mice bearing cancer xenografts with
minimal adverse event, especially in the SCID mice species
(NGS), which show a remarkable tumor suppression.
Speaker Biography
Chin Tarng Lin was a pathology professor and is an emeritus professor right
nowattheCollegeofMedicine,NationalTaiwanUniversity.Hehaspublished
more than 92 papers and obtained 12 patents and has been invited to give
the scientific seminar over 75 times. He has established 10 nasopharyngeal
carcinoma cell lines (NPC-TW01to10) and five endometrioid cancer cell lines
(OV-TW59-P0 to-P4) in his laboratory. He and his colleague have identified
3 specific peptides to localize their targeted proteins, to identify the cancer
xenograft by MRI and to perform peptide-targeted chemotherapy for
different cancers with minimal adverse event.
e:
Notes: